Cholera Vaccines Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The cholera vaccines market was valued at USD 135.09 Million in 2025. It is poised to grow at a CAGR of 12.00% during the forecast period of 2026-2035, and reach USD 419.57 Million by 2035. The market growth is driven by increasing cholera outbreaks, rising immunization programs, strong government vaccination initiatives, and growing global efforts to improve access to preventive healthcare solutions.

Key Market Trends and Insights

• By vaccine type, the killed oral O1 and O139 segment is likely to lead the market, holding around 60% of the market share in the historical period.
• By product, the Dukoral segment is likely to account for over 32% of the market share in the historical period.
• Based on country, the United States is likely to lead the market with a revenue share of around 70% in the historical period.

Market Size and Forecast

• Market Size (2025): USD 135.09 Million
• Projected Market Size (2035): USD 419.57 Million
• CAGR (2026-2035): 12.00%

Cholera Vaccines Market Overview

The market is growing due to rising disease outbreaks, improved immunization programs, and increasing global health initiatives. Expanding vaccine manufacturing capacity and government-led vaccination campaigns are supporting disease prevention efforts. Growing focus on oral vaccine formulations and improved distribution networks is strengthening the adoption of oral cholera vaccine, enhancing global preparedness and reducing cholera-related mortality in endemic regions. The market reached a value of approximately USD 135.09 Million in 2025.

Cholera Vaccines Market Growth Drivers

Global Disease Burden Driving Cholera Vaccine Demand Expansion

Rising infectious disease prevalence and increasing mortality rates across low-resource regions are key growth stimulants. For instance, in January 2026, the WHO reported over 614,000 cholera cases and nearly 7,600 deaths globally in 2025, reflecting persistent outbreak intensity. Additionally, annual estimates indicate 1.3-4.0 million cases and up to 143,000 deaths worldwide. This escalating burden is expected to drive the cholera vaccines market by accelerating immunization demand.

Cholera Vaccines Market Trends

Key trends shaping the market include increasing vaccine stockpiling, expanding global immunization programs, and rising demand for oral cholera vaccines worldwide.

Advancements in Vaccine Development Propelling the Market Demand

Increasing R&D investments and growing focus on scalable vaccine production are shaping industry dynamics. For instance, in May 2025, Bharat Biotech’s oral cholera vaccine Hillchol completed Phase III trials, demonstrating strong immunogenicity and safety. This development is expected to strengthen the cholera vaccines market by enabling large-scale production and addressing persistent global supply shortages.

Cholera Vaccines Market Segmentation

Market Breakup by Vaccine Type

• Whole cell V. cholerae O1 with Recombinant B-subunit
• Killed Oral O1 and O139

Market Breakup by Product

• Vaxchora
• Dukoral
• Shanchol
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Market Breakup by End User

• Hospital and Clinics
• Homecare Settings
• Others

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Cholera Vaccines Market Share

Dukoral Expected to Lead the Market Segment by Product

The Dukoral segment is likely to account for over 32% of the market share in the historical period and is expected to dominate the market. Its strong adoption is supported by proven efficacy, ease of administration, and widespread use in travel and endemic settings. Expanding global immunization initiatives are further strengthening demand for oral cholera vaccine, reinforcing sustained market penetration and product preference globally.

Cholera Vaccines Market Analysis by Region

The United States is likely to lead the market with a revenue share of around 70% in the historical period and is expected to dominate. The leadership position is supported by advanced healthcare infrastructure, strong regulatory frameworks, and high awareness of travel-related vaccination. Increasing emphasis on preventive healthcare and the availability of a vaccine distribution networkare further supporting market expansion across the region.

Leading Players in the Cholera Vaccines Market

The key features of the market report comprise patent analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

EuBiologics Co., Ltd.

Headquartered in Seoul, South Korea, and established in 2010, EuBiologics Co., Ltd. specializes in vaccine development and global supply. Its key cholera vaccine products include Euvichol and Euvichol-Plus, widely used in WHO-supported immunization programs. The company plays a major role in scaling cholera immunization program access across endemic regions and humanitarian vaccination campaigns.

Valneva SE

Headquartered in Saint-Herblain, France, and founded in 2013, Valneva SE is a specialty vaccine company focused on infectious diseases. Its oral cholera vaccine Dukoral is used for prevention in travelers and endemic populations. The company supports global infectious disease control efforts and strengthens vaccine distribution network expansion in preventive healthcare markets.

Sanofi S.A.

Headquartered in Paris, France, and established in 1973, Sanofi S.A. is a global pharmaceutical leader with strong vaccine capabilities through its Sanofi Pasteur division. It contributes to cholera vaccine supply via manufacturing and distribution partnerships. Sanofi supports large-scale immunization initiatives and reinforces global vaccine manufacturing capacity for infectious disease prevention.

Emergent BioSolutions Inc.

Headquartered in Maryland, USA, and founded in 1998, Emergent BioSolutions Inc. is a biopharmaceutical company focused on vaccines and medical countermeasures. Its portfolio includes Vaxchora, the first FDA-approved oral cholera vaccine for travelers. The company supports outbreak preparedness and strengthens travel vaccine protection strategy in global infectious disease management.

Other key players in the market are PaxVax Inc., Shantha Biotechnics Limited, Astellas Pharma Inc., Incepta Vaccine Ltd., Vabiotech, and Hilleman Laboratories.

Key Questions Answered in the Cholera Vaccines Market Report

• What was the cholera vaccines market value in 2025?
• What is the cholera vaccines market forecast outlook for 2026-2035?
• What major factors aid the demand for cholera vaccines market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major cholera vaccines market trends?
• Which vaccine type is expected to dominate the market segment?
• Which product is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the cholera vaccines market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?